Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Global Blood Glucose Monitoring Devices Market to Reach USD 13 Billion by 2023

By LabMedica International staff writers
Posted on 16 Mar 2020
The global blood glucose monitoring devices (BGMDs) market was valued at nearly USD 8 billion in 2018 and is projected to grow at a fast-paced CAGR of approximately 11% to reach USD 13 billion by 2023, driven by the phenomenal sales growth of new revolutionary continuous glucose monitoring systems (CGMs). More...
However, the growth of CGMs will be offset by a steady decline in the blood glucose meters (BGMs) segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.

These are the latest findings of Research and Markets (Dublin, Ireland), a leading market research store.

The overall BGMDs market is being driven by several positive factors, including a strong demand for discreet, accurate CGM devices that provide convenient blood glucose monitoring 24/7 and eliminate frequent/cumbersome and painful fingersticks; steadily increasing awareness and adoption of new, next-generation CGMs on the back of strong sales/marketing/advertising and physician referrals; solid clinical outcomes due to the ability to improve the accuracy of insulin delivery and improve glycemic control or time-in-range (TIR) via continuous (24/7) glucose monitoring; the ability to integrate lucrative CGM sensors into fast-growing next-generation hybrid closed-loop insulin pump systems, better patient awareness and physician understanding of glucose trends and impact of diet/medication/exercise/lifestyle factors due to the use of smartphone-driven digital health coaching apps, resulting in improved diabetes management; ability to lower overall healthcare costs; solid reimbursement; low CGM market penetration (due to newness of technology), leaving much room for market growth in a large and expanding diabetes population; and sales of lucrative recurring CGM disposables (sensors) and accessories.

Related Links:
Research and Markets


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Legionella Pneumophila Test
CHORUS Legionella Urinary Antigen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.